Ariceum reports promising data for new lung cancer treatment

Berlin, Germany-based Ariceum Therapeutics has presented data at the European Association of Nuclear Medicine 2024 conference on its first-in-class radiopharmaceutical drug, 225Ac-satoreotide.

The somatostatin receptor 2 (SSTR2) antagonist is being developed for the treatment of small cell lung cancer (SCLC), a difficult-to-treat form of the disease which accounts for about 10%-15% of all lung cancers.

While most current treatments for SCLC involve a combination of chemotherapy, radiation, and immunotherapy, Ariceum’s latest data, based on pre-clinical studies, suggests that 225Ac-satoreotide has the potential to improve outcomes.